Recently, the successful applications of radiomics in ovarian cancer, including cancer detection, differentiation diagnosis, prediction of treatment response, survival and lymph node metastasis [21, 28–33], suggested that radiomics may hold potential for decoding the CCR5 status in patients with ovarian cancer. Here, CCR5 is linked to ovarian carcinoma.